Clinical Trials Logo

Tuberculosis, Pulmonary clinical trials

View clinical trials related to Tuberculosis, Pulmonary.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03941496 Withdrawn - Clinical trials for Tuberculosis, Pulmonary

Azacytidine During Anti-tuberculosis Therapy

AZA
Start date: October 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Tuberculosis has been shown to make immune genes inaccessible and slows immune response The purpose of this research is to see if if azacitidine is safe and can return the ability of the body to resist tuberculosis (TB), a contagious infection that attacks the lungs. Individuals with tuberculosis are being asked to participate. Some will receive a drug to restore a host immunity while others can choose to receive standard of care. All patients will continue to receive standard of care tuberculosis therapy regardless of whether they chose to participate in the study. This study is a Phase Ib/IIa single-institution, open-label, non-randomized clinical trial of sub-cutaneous azacitidine in pulmonary TB patients during the continuation phase of ATT.

NCT ID: NCT03862248 Withdrawn - Clinical trials for Tuberculosis, Pulmonary

Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More

TriDoRe
Start date: September 30, 2019
Phase: Phase 3
Study type: Interventional

Drug-resistance is a major challenge for tuberculosis (TB) care programs. The new WHO guideline recommends adding levofloxacin in previously treated patients with isoniazid-resistant rifampicin-susceptible TB. The investigators believe that such a retreatment regimen may result in acquired resistance to fluoroquinolone, the core drug of multidrug-resistant TB (MDR-TB) regimen, and thus threaten the effectiveness of the fluoroquinolone-based MDR-TB treatment regimen. Therefore the investigators propose to study if regimens strengthened by using high-dose first-line drugs, either a triple dose of isoniazid or a triple dose of rifampicin, are non-inferior to the WHO recommended levofloxacin-strengthened regimen. If one of both high-dose regimens would be non-inferior, it could replace the levofloxacin-strengthened regimen.

NCT ID: NCT03732014 Withdrawn - Clinical trials for Tuberculosis, Pulmonary

Bronchial Washings in Sputum Scarce Cases of Pulmonary Tuberculosis

Start date: January 2, 2019
Phase:
Study type: Observational

This study will be conducted in Ojha Institute of Chest Diseases and Department of Medicine, Dow Medical College, Karachi both affiliated with Dow University of Health Sciences, Karachi, Pakistan after IRB approval. All patients of either gender with clinical suspicion of PTB on history, examination and CXR and not expectorating sputum or less than 1 ml will be included in the study. Patients with extra pulmonary tuberculosis, those with age < 12 years will be excluded. Demographic data of selected patients including age, gender, contact with PTB patient will be collected. Data will be entered in study proforma. Selected patients will undergo bronchoscopy using Olympus 180 series video bronchoscope. Bronchial Wash will be done and 3 aliquots of BW samples will be collected by suctioning. One part of washing will be immediately inoculated in AFB Culture media and second will be submitted for Xpert MTB/RIF testing. Third part will be centrifuged, and sediment will be subjected to AFB microscopy after staining with Ziehl-Neelsen technique. Results of microscopy and Xpert MTB/RIF will be collected next day, and treatment will be started if MTB comes positive, while results of AFB Culture will be collected after 6 weeks and treatment will be started if not already started on previous reports. Sensitivity/Resistance pattern will be recorded for both Xpert MTB/RIF and ABF Culture. The sample size of 72 was taken for conduct of study. Sample size calculations were done using PASS software version 15.0. Frequency of positive tests will be calculated. Mean age will be calculated according to gender and compared by Student's t-test. Sensitivity & specificity of tests will be calculated using online calculator by VassarStats. Frequency of positive yield of Xpert MTB/RIF will be compared to that of microscopy by χ2- test. P-value of <0.05 was considered significant.

NCT ID: NCT03277742 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz

Start date: September 20, 2017
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate an integral strategy in which diabetes mellitus 2 (DM2) and pulmonary tuberculosis (TB) are managed together. The researchers propose a community intervention with two arms in 4 health centers in Orizaba, Veracruz. Patients will be assigned to either arm by convenience. One arm will receive the joint treatment strategy and another the routine treatment used in health services.

NCT ID: NCT03159975 Withdrawn - Clinical trials for Pulmonary Tuberculoses

Safety and Immunogenicity Study of GX-70 in TB Patient

Start date: March 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and immunogenicity in patients with pulmonary tuberculosis of an investigational DNA vaccine being developed for the prevention of relapse of tuberculosis.

NCT ID: NCT00517231 Withdrawn - Clinical trials for Pulmonary Tuberculosis

Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment

Start date: June 2005
Phase: N/A
Study type: Observational

Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy.

NCT ID: NCT00414414 Withdrawn - HIV Infections Clinical Trials

A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection

Start date: February 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if 30-day survival will be improved with addition of prednisone to standard tuberculosis (TB) therapy.

NCT ID: NCT00374517 Withdrawn - Clinical trials for Refractory Pulmonary Tuberculosis

Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs

Start date: September 5, 2006
Phase: Phase 2
Study type: Interventional

This study will determine whether a drug called pimonidazole hydrochloride shows areas of low oxygen in tuberculosis (TB)-infected lungs. Pimonidazole is a "low oxygen marker," an agent designed to find areas in the body that are not getting enough oxygen. If it is found that TB grows where oxygen is low, these results may help doctors decide what medicines would be most effective for treating TB. Patients 20 years of age or older who are scheduled for lung surgery at the National Masan Tuberculosis Hospital in Masan, Korea to treat their TB may be eligible for this study. Participants undergo the following procedures: - Blood draw before surgery to test for hepatitis B and hepatitis C viruses. - Pregnancy test for women who can become pregnant. - Infusion of pimonidazole through a vein in the arm 24 hours before surgery. A part of the patient's lung is removed during surgery. This tissue is examined under a microscope for evidence of pimonidazole, which would indicate low oxygen. - Blood sample collection during surgery and on the 7th and 14th days after surgery to check liver function.